复宏汉霖-Ｂ(02696.HK)向Accord US授予HLX02注射用曲妥珠单抗于美国和加拿大独家开发与商业化权益
格隆汇9月30日丨复宏汉霖-Ｂ(02696.HK)公布，公司已于近日与Accord Healthcare Inc. (Accord US) 订立一份具约束力条款概要，据此，公司同意向Accord US授予一项许可，供其于美国及加拿大开发及商业化HLX02注射用曲妥珠单抗（中国境内商品名：汉曲优；欧盟商品名：Zercepac）。
许可产品在区域内的许可总里程碑付款包括：首付款2700万美元，于签署用于规范该安排的正式协议后支付；监管里程碑付款合计不超过1300万美元，根据许可产品在美国内的药物代谢动力学研究进度及上市申请进度支付；及于区域内许可产品商业化后，商业销售里程碑付款2500万美元，于许可产品在区域内每取得5亿美元的累计净销售额时支付。被许可方亦将根据许可产品年度净利润的水准向许可方支付许可产品净利润的18%至50%的分层特许权使用费。
截至本公告日期，公司已与多个合作伙伴（包括Accord Healthcare Limited、雅各臣药业（香港）有限公司、Cipla Limited及Mabxience Research,S.L.）就HLX02订立许可及商业化协议，以便成功于中国境外（包括中国香港、中国澳门、马来西亚、澳洲、纽西兰、哥伦比亚、阿根廷、乌拉圭、巴拉圭，以及欧洲、中东－北非及独联体等80多个司法权区及地区）进行HLX02的商业化。
据悉，Accord US与Accord Healthcare Limited（集团就HLX02注射用曲妥珠单抗于欧盟等地区的合作伙伴）同为Intas的附属公司。Accord US于2005年在美国注册成立，专注于医院市场领域，且聚焦于肿瘤学、中枢神经和其他重症监护领域，目前已获得129项仿制药批准。Intas成立于1976年，总部位于印度，主要从事全球范围内的药物制剂成品、活性药物成分、医疗器械和医疗用品的制造、营销、分销及销售。
公司表示，集团已就HLX02注射用曲妥珠单抗于欧盟等地区商业化与Accord Healthcare Limited建立良好合作关系。本次与Accord US就HLX02注射用曲妥珠单抗于美国和加拿大的商业化合作将有助于进一步推进HLX02注射用曲妥珠单抗海外市场拓展，并加强集团产品的可及性和国际影响力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
